West Pharmaceutical Services (WST) EBIT (2009 - 2026)

West Pharmaceutical Services (WST) has 18 years of EBIT data on file, last reported at $177.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 65.51% year-over-year to $177.1 million; the trailing twelve-month figure through Mar 2026 stood at $655.0 million (up 18.21% YoY), and the FY2025 full-year result was $584.9 million, up 2.63% from the prior year.
• EBIT advanced to $177.1 million in Q1 2026, from $156.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $228.4 million in Q2 2022 to a low of $107.0 million in Q1 2025.
• A 5-year average of $161.3 million and a median of $160.9 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT slumped 30.85% in 2024 and jumped 65.51% in 2026, its largest moves.
• Tracing WST's EBIT over 5 years: stood at $129.7 million in 2022, then gained by 24.06% to $160.9 million in 2023, then declined by 0.81% to $159.6 million in 2024, then fell by 1.88% to $156.6 million in 2025, then increased by 13.09% to $177.1 million in 2026.
• Business Quant data shows WST's EBIT at $177.1 million in Q1 2026, $156.6 million in Q4 2025, and $167.6 million in Q3 2025.